论文部分内容阅读
近几年,在美国临床肿瘤学会(ASCO)每年评出的重要成果中,约有1/3～1/4与分子靶向治疗相关。2008年,同样有3项这方面的研究成果入选。在这份由21名顶尖肿瘤学家参与评选的报告中显示,西妥昔单抗联合化疗治疗表达表皮生长因子受体(EGFR)的非小细胞肺癌(NSCLC)患者能显著提高生存率:西妥昔单抗仅对携带野生型K-ras基因的结肠癌患者有明显疗效;贝伐单抗因能阻断新生血管的形成,已被美国食品药品管理局(FDA)批准用于大肠癌和肺癌的治疗:FDA又批准贝伐单抗联合紫杉醇用于Her-2阴性的转移性乳腺癌患者的一线治疗。
In recent years, about one-third to one-quarter of the important results that have been assessed annually by the American Society for Clinical Oncology (ASCO) have been associated with molecular targeted therapy. In 2008, there were also three research results in this area. In this report by 21 leading oncologists, cetuximab in combination with chemotherapy for patients with non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR) significantly improves survival: Western Tuxiximab is only effective in patients with colon cancer carrying the wild-type K-ras gene; bevacizumab has been approved by the U.S. Food and Drug Administration (FDA) for use in colorectal cancer because it blocks neovascularization. Treatment of lung cancer: The FDA also approved bevacizumab in combination with paclitaxel for first-line treatment of patients with Her-2 negative metastatic breast cancer.